| Add to balance / Manage account | User: | Log out |
| Prospect News home > News index > List of issuers H > Headlines for Human BioSystems, Inc. > News item |
Human BioSystems gets patent for preservation of blood platelets
By Elaine Rigoli
Tampa, Fla., Aug. 2 - Human BioSystems said Wednesday that it received its fourth patent - No. 7,083,910, "Preservation of Blood Platelets with Citrate" - from the U.S. Patent Office, which will contribute in the area of blood-platelet preservation for cancer patients who have undergone chemotherapy and/or radiation treatment and trauma patients suffering from extensive bleeding.
Blood platelets are the congealing component in blood. Before platelets can be released to the medical community for use by human patients, they must undergo a number of tests to assure their purity, which can take one to two days to complete.
Then they must be transported to the medical facilities, which can add more time. Thus, there is a very limited shelf life left for the platelets once they are available for use, the company said in a news release.
"Our newest patent covers the process of cooling blood platelets to near zero degrees Centigrade to keep them fresh and preserved for greater than the current standard of five days. We anticipate being able to extend this process to seven days and beyond. This will reduce the current need to discard stored platelets that have been preserved by existing methods," president David Winter said in the release.
"By developing a cooling method that prolongs the preservation of platelets, we believe this will greatly reduce the risk of bacterial infection while increasing the availability of essential medical resources required to treat cancer and trauma patients."
Human BioSystems develops preservation platforms for organs and other biomaterials and is located in Palo Alto, Calif.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.